KYNTRA BIO, INC. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Kyntra Bio, Inc. filed a Form 8-K on October 6, 2026, reporting Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has received a delisting notice, though the specific exchange, rule violated, cure period, and remediation details are not provided in the extracted text available.
Why this rating
Delisting threat is business-changing for any public company; relative to $21M market cap, loss of public listing status is existential risk.
Extracted items
Price action (we called it negative)
before filing · preread $5.96 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.